48 /100
MEDIUM RISK
Score updated May 30, 2026

CHRS — Coherus Oncology, Inc. Dilution Risk Tracker

Track CHRS dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track CHRS — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
0
📊 Float Risk
17
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

⛈️
Warning
High probability of dilution event
42%
🔁 Convertible Conversion 60%
• Major convertible overhang: 33% potential dilution
• Convertible risk score very high (85/100)
🔄 Reverse Split 30%
• 50-day avg $1.71 approaching $1 threshold
💰 Capital Raise 18%
• Active ATM program with $50M remaining capacity
🔔 Track CHRS — Get forecast alerts →

💹 Market Data

Market Cap$245.26M
Shares Outstanding154.25M
Float132.53M
Cash$167.05M
Debt$54.37M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↓ 3.7% shares (2025Q4 vs prior)
127 institutional holders · 52.49M shares
#1 BlackRock, Inc. 10.56M shares
#2 VANGUARD GROUP INC 10.03M shares
#3 Kohlberg Kravis Roberts & Co. L.P. 3.04M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest28.11M
Days to Cover17.2
% of Float21.2%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2021
xbrl XBRL WARRANT Dec 31, 2014
8-K 8K EVENT Feb 17, 2026
424B5 ATM Feb 13, 2026
424B5 ATM Feb 12, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track CHRS Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking CHRS — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for CHRS
📊 CHRS FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 CHRS Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.